Gemcitabine plus Platinum Combination Chemotherapy in Patients with Metastatic Cancer who suffer from Severe and Irreversible Hepatic Impairment: A Single Center Experience

Basit Öğe Kaydı
dc.authoridsezer, ahmet/0000-0002-6445-1439
dc.authoridMertsoylu, Huseyin/0000-0002-1932-9784
dc.authoridKose, Fatih/0000-0002-0156-5973
dc.authoridOzyilkan, Ozgur/0000-0001-8825-4918
dc.authoridSumbul, Ahmet Taner/0000-0002-5573-906X
dc.contributor.authorSezer, Ahmet
dc.contributor.authorSumbul, Ahmet Taner
dc.contributor.authorAbali, Huseyin
dc.contributor.authorMertsoylu, Huseyin
dc.contributor.authorMuallaoglu, Sadik
dc.contributor.authorKose, Fatih
dc.contributor.authorOzyilkan, Ozgur
dc.date.accessioned2024-09-18T20:32:49Z
dc.date.available2024-09-18T20:32:49Z
dc.date.issued2014
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractThere is limited information on chemotherapeutic agent doses suitable for patients with metastatic cancer who suffer from and irreversible hepatic impairment and who could potentially benefit from chemotherapy and on their results. In this retrospective study, we aimed to share our center's experience of Gemcitabine + Platinum Combination chemotherapy in these patients. Data of 13 patients matching the criteria were analyzed. In our study the patients were treated with a dose of Gemcitabine + Platinum Combination, 50% of the original dose and the dose was increased gradually on the following days. Thirteen of one patient was given Gemcitabine & Carboplatin protocol and the others were given Gemcitabine & Cisplatin. In 42 chemotherapy cycles in total grade 3-4 thrombocytopenia occure after 7 cycles, grade 3-4 neutropenia was not observed While liver functions in 8 patients improved slightly, no change was observed in 2 patients and in 3 patients they deteriorated. Total survival period was calculate as 3.78 (95CI%: 0,17-7.54) months. As a consequence Gemcitabine + Platinum Combination chemotherapy in patients with metastatic cancer who suffer from severe and irreversible hepatic impairment can be implemented when clinical benefits are expected.en_US
dc.identifier.doi10.5754/hge14588
dc.identifier.endpage1900en_US
dc.identifier.issn0172-6390
dc.identifier.issue135en_US
dc.identifier.pmid25713885en_US
dc.identifier.startpage1895en_US
dc.identifier.urihttps://doi.org/10.5754/hge14588
dc.identifier.urihttps://hdl.handle.net/20.500.12483/11142
dc.identifier.volume61en_US
dc.identifier.wosWOS:000346326200010en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherH G E Update Medical Publishing S Aen_US
dc.relation.ispartofHepato-Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMetastatic canceren_US
dc.subjectHepatic impairmenten_US
dc.subjectChemotherapyen_US
dc.titleGemcitabine plus Platinum Combination Chemotherapy in Patients with Metastatic Cancer who suffer from Severe and Irreversible Hepatic Impairment: A Single Center Experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu